POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria, Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21.
Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa
Northstar Medical Radioisotopes and POINT Biopharma today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).